• 2025 revenue of $37.1 million, up 4% year-over-year, and 71% Full-year gross margins
• Enhanced Balance Sheet Flexibility with an Additional $2.5 million Proceeds from Amended Credit Facility in November
• Implemented Strategic Workforce and Cost Reduction Program in Q4 to Accelerate Timing to Cash Flow Breakeven in 2026
• Ongoing Interactive Discussions with FDA to Determine Content and Timing of New De Novo Application for DrugSorb™ -ATR

PRINCETON, N.J., March 25, 2026 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the fourth quarter and full year ended December 31, 2025, and recent business highlights. 

Full Year 2025 Financial Results

• Revenue was $37.1 million, an increase of 4% compared to $35.6 million in 2024, or flat on a constant currency basis.
• Gross margin was 71% in 2025 compared to 70% in 2024.
• Operating loss for 2025 improved by 10% to $14.7 million compared to $16.5 million in 2024.
• Net loss, improved to $8.2 million or $0.13 per share, compared to net loss of $20.7 million or $0.38 per share in 2024.
• Adjusted net loss for 2025 was $14.2 million, or $0.23 per share, compared to an adjusted net loss of $12.7 million, or $0.23 per share, in 2024.
• Adjusted EBITDA loss for 2025 improved to $10.5 million, compared to a loss of $11.5 million in 2024.

Fourth Quarter 2025 Financial Results

• Revenue was $9.2 million, an increase of 1% over the prior year, and down 8% on a constant currency basis. 
• Gross margin expanded to 74% in the quarter compared to 70% in Q4 2024.
• Operating loss, which included a restructuring charge of approximately $0.5 million due to our Q4 workforce and cost reduction program, was $4.6 million, compared to $3.7 million in Q4 2024. 
• Net loss was $5.5 million or $0.09 per share, compared to a net loss of $7.6 million or $0.14 per share in Q4 2024.
• Adjusted net loss was $4.3 million or $0.07 per share, compared to an adjusted net loss of $1.7 million or $0.03 per share in Q4 2024, which includes a net income tax benefit accrual of $1.7 million recorded in Q4 2024 from the sale of Net Operating Loss and R&D tax credits.
• Adjusted EBITDA loss was $3.2 million compared to a loss of $2.4 million in Q4 2024.
• Total cash, cash equivalents, and restricted cash of $7.8 million on December 31, 2025, compared to $9.1 million as of September 30, 2025. 

“2025 was a transitional year for our business as we made good progress in four key objectives,” stated Dr. Phillip Chan, Chief Executive Officer of CytoSorbents. “We ended the year with positive clinical and commercial momentum for 2026, with a lower cost structure and improved balance sheet to support our growth.  Additionally, we continue to make progress with the FDA to align on the content and timing of a new De Novo submission for DrugSorb-ATR™ and look forward to providing further updates in the future.   Four key areas of focus include the following:

A.  Sales Performance

Sales in 2025 grew by 4% to $37.1 million led by a 13.0% increase in direct sales outside of Germany to $8.6 million and an 11.4% increase in distributor sales to $16.5 million, that together accounted for approximately 68% of our business.  This was offset by a 10% reduction in Germany sales to $11.8 million, reflecting the near-term impact of our proactive restructuring of German sales operations and the implementation of strategies that are expected to drive more consistent and scalable growth.  Improvements implemented during this initiative include enhanced customer targeting, structured weekly sales planning, increased focus on new account development, and improved allocation of sales resources. Early indicators in 2026 suggest improving commercial activity, including increased customer engagement and new account development.  We are encouraged by these signs and expect to see incremental improvement across the year.

B.  Clinical Momentum

By the end of 2025, we surpassed a key milestone of more than 300,000 cumulative CytoSorb® treatments delivered globally – an increase of more than 50% over the past few years – highlighting the broad and growing adoption of our therapy across more than 70 countries and a wide range of clinical applications. 

As highlighted at last week’s International Symposium of Critical Care and Emergency Medicine (ISICEM) conference, a steady stream of new clinical data continues to support the use of CytoSorb across multiple critical care indications.  Sepsis and septic shock remain among the leading use cases.

• A recent multinational survey of 442 physicians, endorsed by ESICM and SIAARTI and published in Intensive Care Medicine Experimental (2026), found that more than three-quarters of respondents use extracorporeal blood purification primarily for refractory septic shock, with broad-spectrum hemoadsorption such as CytoSorb identified as the most commonly used and preferred modality (43%). 
• During World Sepsis Day and Sepsis Awareness Month in September 2025, we hosted a webinar entitled, “Turning the Tide in Sepsis and Septic Shock” highlighting why and how CytoSorb is used to control deadly inflammation, stabilize patients, reverse capillary leak, and facilitate fluid removal from patients.  
• Interim results from the septic shock cohort of the prospective COSMOS (CytOSorb TreatMent Of Critically Ill PatientS) registry, published in Annals of Intensive Care (2026), evaluated 140 patients across 18 sites. Treatment with CytoSorb was associated with highly significant reductions (p

  The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.